3Petty GW, Brown RD Jr, Whisnant JP, et al. Survival and recurrence after first cerebral infarction : a population-based study in Rochester,Minnesota, 1975 through 1989. Neurology, 1998, 50:208 - 216.
4Pearson TA, Blair SN, Daniels SR, et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update:consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases.Circulation, 2002, 106:388 - 391.
5Hilleman DE, Lucas BD Jr. Angiotensin-converting enzyme inhibitors and stroke risk:benefit beyond blood pressure reduction? Pharmacotherapy, 2004, 24.. 1064 - 1076.
6Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin - converting - enzyme inhibitor, ramipril, on cardiovascular events in high - risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med, 2000, 342:145 - 153.
7Progress Collaborative Group. Randomised trial of a perindoprilbased blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaernic attack. Lancet, 2001, 358:1033 - 1041.
8Lewis SJ, Moye LA, Sacks FM, et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. Ann Intern Med, 1998, 129:681 - 689.
9Bhatt DL, Kapadia SR, Yadav JS, et al. Update on clinical trials of antiplatelet therapy for cerebrovaseular diseases. Cerebrovase Dis, 2000, 10(Suppl 5):34 - 40.
10Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet, 2004, 364: 331 - 337.
4Sacco RL, Foulkes MA, Mohr JP, et al. Determinants of early re- currence of cerebral infarction. The stroke data bank[J]. Stroke, 1989(20) .- 983.
5Sacco RL, Wolf PA, Kannel WB, et al. Survival and recurrence fol- lowing stroke : The Framingham study[J]. Stroke, 1982 (13) : 290 - 295.
6王陇德.脑卒中高危人群的筛查[M].北京:卫生部脑卒中筛查与防治工程委员会,2012:2-4.
7Saceo R, Wolf P, Kannel W, et al. Survival and recurrence fol lowing stroke: The framingham study[J~. Stroke, 1982 (13) : 290-295.
8Gum P, Kottke M, Welsh P, et al. A prospective, blinded de- termination of the natural history o{ aspirin resistance among stable patients with cardiovascular disease [J]- Coil Cardiol, 200a,41(6) = 961 965.
9Morrow J. The isoprostanes:their quantification as an index of oxidant stress status in vivo[J~. Drug Metab Rev, 2000,32 (3- 4) :377 385.
10Lepantalo A, Mikkelsson J, Resendiz J, et al. Polymorphisms of COX-1 and GPVI associate with the antiplatelet effect of as- pirin in coronary artery disease patients[J]. Thromb Haemost, 2006,95(2) : 253 259.
